Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Inclusion Criteria:

• Histologically confirmed advanced solid tumor with specific KRAS G12 mutations (doseescalation) or RAS mutations (dose optimization/expansion) identified throughdeoxyribonucleic acid (DNA) sequencing. PDAC with wild-type RAS (expansion).

• Treatment naive or have received prior standard therapy appropriate for tumor typeand stage

• Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Adequate organ function

Exclusion Criteria:

• Primary central nervous system (CNS) tumors

• Active, untreated brain metastases

• Known or suspected impairment of gastrointestinal function that may prohibit abilityto swallow or absorb an oral medication

• History of any other unstable or clinically significant concurrent medical conditionthat would, in the opinion of the investigator, jeopardize the safety of aparticipant, impact their expected survival through the end of the studyparticipation, and/or impact their ability to comply with the protocolprior/concomitant therapy

Other inclusion/exclusion criteria may apply.